GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » Issuance of Debt

Oruka Therapeutics (FRA:HQ1) Issuance of Debt : €0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Issuance of Debt?

Oruka Therapeutics's Issuance of Debt for the six months ended in Mar. 2024 was €0.00 Mil.

Oruka Therapeutics's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.


Oruka Therapeutics Issuance of Debt Historical Data

The historical data trend for Oruka Therapeutics's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Issuance of Debt Chart

Oruka Therapeutics Annual Data
Trend Dec24
Issuance of Debt
-

Oruka Therapeutics Semi-Annual Data
Mar24
Issuance of Debt -

Oruka Therapeutics Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oruka Therapeutics Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Oruka Therapeutics Business Description

Traded in Other Exchanges
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics Headlines

No Headlines